JP2013138681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013138681A5 JP2013138681A5 JP2013048777A JP2013048777A JP2013138681A5 JP 2013138681 A5 JP2013138681 A5 JP 2013138681A5 JP 2013048777 A JP2013048777 A JP 2013048777A JP 2013048777 A JP2013048777 A JP 2013048777A JP 2013138681 A5 JP2013138681 A5 JP 2013138681A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- stranded rna
- region
- rna nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 11
- 230000001629 suppression Effects 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 229920000570 polyether Polymers 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 101150112014 Gapdh gene Proteins 0.000 description 8
- 0 CC(C)C(C)(CCC(C)C(C)O**)CCN1C(COC)CCC1 Chemical compound CC(C)C(C)(CCC(C)C(C)O**)CCN1C(COC)CCC1 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 101150077556 LMNA gene Proteins 0.000 description 1
- 101100127662 Mus musculus Lama1 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- -1 sulfur-substituted monophosphate Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013048777A JP5555346B2 (ja) | 2010-08-03 | 2013-03-12 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010174915 | 2010-08-03 | ||
| JP2010174915 | 2010-08-03 | ||
| JP2010230806 | 2010-10-13 | ||
| JP2010230806 | 2010-10-13 | ||
| JP2010269823 | 2010-12-02 | ||
| JP2010269823 | 2010-12-02 | ||
| JP2011152381 | 2011-07-08 | ||
| JP2011152381 | 2011-07-08 | ||
| JP2013048777A JP5555346B2 (ja) | 2010-08-03 | 2013-03-12 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012026878A Division JP5261677B2 (ja) | 2010-08-03 | 2012-02-10 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013138681A JP2013138681A (ja) | 2013-07-18 |
| JP2013138681A5 true JP2013138681A5 (enExample) | 2013-08-29 |
| JP5555346B2 JP5555346B2 (ja) | 2014-07-23 |
Family
ID=45559420
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537085A Expired - Fee Related JP4965745B2 (ja) | 2010-08-03 | 2011-07-28 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
| JP2012026878A Expired - Fee Related JP5261677B2 (ja) | 2010-08-03 | 2012-02-10 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
| JP2013048777A Expired - Fee Related JP5555346B2 (ja) | 2010-08-03 | 2013-03-12 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537085A Expired - Fee Related JP4965745B2 (ja) | 2010-08-03 | 2011-07-28 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
| JP2012026878A Expired - Fee Related JP5261677B2 (ja) | 2010-08-03 | 2012-02-10 | 含窒素脂環式骨格を有する一本鎖核酸分子 |
Country Status (9)
| Country | Link |
|---|---|
| EP (4) | EP2436767B1 (enExample) |
| JP (3) | JP4965745B2 (enExample) |
| KR (3) | KR101849801B1 (enExample) |
| CN (3) | CN104004018B (enExample) |
| DK (1) | DK2674494T3 (enExample) |
| ES (4) | ES2533129T3 (enExample) |
| PT (1) | PT2674494E (enExample) |
| TW (2) | TWI572716B (enExample) |
| WO (1) | WO2012017919A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
| WO2013077446A1 (ja) * | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
| US9404108B2 (en) | 2012-03-04 | 2016-08-02 | Bonac Corporation | Micro-RMA inhibitor |
| WO2013133393A1 (ja) * | 2012-03-07 | 2013-09-12 | 学校法人東京医科大学 | Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子 |
| US20150105442A1 (en) * | 2012-03-29 | 2015-04-16 | Aqua Therapeutics Co., Ltd. | Nucleic Acid Molecule Capable of Inhibiting Expression of Periostin Gene, method for Inhibiting Expression of Periostin Gene, and Use of Said Nucleic Acid Molecule |
| US9663784B2 (en) | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| US20160304866A1 (en) * | 2013-09-27 | 2016-10-20 | Aqua Therapeutics Co., Ltd. | Drug for Disease Caused by Expression of Periostin Except Eye Disease, and Use Thereof |
| WO2015093495A1 (ja) * | 2013-12-16 | 2015-06-25 | 株式会社ボナック | ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子 |
| CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
| CN106068324B (zh) * | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
| WO2015099188A1 (ja) * | 2013-12-27 | 2015-07-02 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途 |
| HK1244035A1 (en) * | 2014-12-15 | 2018-07-27 | Bonac Corporation | Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression |
| BR112017013664A2 (pt) * | 2014-12-27 | 2018-03-13 | Bonac Corporation | mirna de tipo natural, composição, métodos para inibir expressão de um gene alvo e para tratar uma doença, e, ácido nucleico de fita simples. |
| HK1244031A1 (en) | 2015-03-27 | 2018-07-27 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| JPWO2016167366A1 (ja) * | 2015-04-17 | 2018-04-05 | 国立大学法人 東京大学 | 眼疾患治療剤 |
| PL3369816T3 (pl) | 2015-10-30 | 2024-07-22 | Toray Industries, Inc. | KOMPOZYCJA STABILNIE ZAWIERAJĄCA CZĄSTECZKĘ JEDNONICIOWEGO KWASU NUKLEINOWEGO, KTÓRA HAMUJE EKSPRESJĘ GENU TGF-β1 |
| JP6634095B2 (ja) | 2015-12-29 | 2020-01-22 | 国立大学法人北海道大学 | プロレニン遺伝子またはプロレニン受容体遺伝子の発現を抑制する一本鎖核酸分子およびその用途 |
| EP3409779A4 (en) * | 2016-01-26 | 2019-07-03 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11518994B2 (en) | 2016-01-30 | 2022-12-06 | Bonac Corporation | Artificial single guide RNA and use thereof |
| CN109071579B (zh) * | 2016-04-26 | 2021-05-14 | 住友化学株式会社 | 单链核酸分子用单体的制造方法 |
| MX2019009305A (es) | 2017-02-06 | 2019-09-19 | Nissan Chemical Corp | Oligonucleotido de cadena simple. |
| JPWO2018182008A1 (ja) | 2017-03-31 | 2020-02-06 | 株式会社ボナック | 遺伝子発現制御機能を有する環状型核酸分子 |
| JPWO2018199338A1 (ja) * | 2017-04-27 | 2020-03-12 | 国立大学法人広島大学 | Ｂ型肝炎治療用核酸分子 |
| SG11201913541QA (en) * | 2017-07-28 | 2020-02-27 | Kyorin Pharmaceutical Co Ltd | Therapeutic agent for fibrosis |
| US20210188895A1 (en) | 2017-10-13 | 2021-06-24 | Bonac Corporation | Single-stranded nucleic acid molecule, and production method therefor |
| TWI830718B (zh) * | 2018-02-09 | 2024-02-01 | 日商住友化學股份有限公司 | 核酸分子之製造方法 |
| EP3770256A4 (en) | 2018-03-20 | 2021-12-22 | Tokyo Institute of Technology | OLIGONUCLEOTIDE ANTISENS WITH REDUCED TOXICITY |
| US11920131B2 (en) | 2018-03-30 | 2024-03-05 | Toray Industries, Inc. | Method of producing hairpin single-stranded RNA molecule |
| US20210115485A1 (en) | 2018-03-30 | 2021-04-22 | Sumitomo Chemical Company, Limited | Method for producing single-strand rna |
| JP7405086B2 (ja) * | 2018-10-02 | 2023-12-26 | 東レ株式会社 | ヘアピン型一本鎖ｒｎａ分子の製造方法 |
| JP7241098B2 (ja) | 2019-01-25 | 2023-03-16 | 杏林製薬株式会社 | 線維症治療剤 |
| WO2020202952A1 (ja) | 2019-03-29 | 2020-10-08 | 住友化学株式会社 | 無機多孔質担体、及びこれを用いた核酸の製造方法 |
| EP3950695A4 (en) | 2019-03-29 | 2023-01-25 | Sumitomo Chemical Company, Limited | PROCEDURE FOR PRODUCTION OF RNA |
| WO2020202953A1 (ja) | 2019-03-29 | 2020-10-08 | 住友化学株式会社 | 無機多孔質担体、及びこれを用いた核酸の製造方法 |
| WO2020202951A1 (ja) | 2019-03-29 | 2020-10-08 | 住友化学株式会社 | 無機多孔質担体、及びこれを用いた核酸の製造方法 |
| US12371451B2 (en) | 2019-03-29 | 2025-07-29 | Sumitomo Chemical Company, Limited | Inorganic porous carrier and method for producing nucleic acids using same |
| JP7640461B2 (ja) | 2019-10-11 | 2025-03-05 | 住友化学株式会社 | 核酸オリゴマーの製造方法 |
| CN115003682A (zh) | 2020-01-29 | 2022-09-02 | 住友化学株式会社 | 核酸寡聚物的制造方法 |
| US12391716B2 (en) | 2020-01-29 | 2025-08-19 | Sumitomo Chemical Company, Limited | Process of preparing nucleic acid oligomer |
| WO2021193954A1 (ja) | 2020-03-27 | 2021-09-30 | 住友化学株式会社 | 核酸オリゴマーの製造方法 |
| US20230256425A1 (en) | 2020-05-13 | 2023-08-17 | Sumitomo Chemical Company, Limited | Inorganic porous substrate, inorganic porous support, and nucleic acid production method |
| EP4180442A4 (en) | 2020-07-09 | 2025-05-14 | Sumitomo Chemical Company, Limited | METHOD FOR PRODUCING A NUCLEIC ACID OLIGOMER |
| US20240051986A1 (en) * | 2020-09-24 | 2024-02-15 | Sumitomo Chemical Company, Limited | Method for producing nucleic acid oligomer |
| EP4410770A1 (en) | 2021-09-28 | 2024-08-07 | Sumitomo Chemical Company, Limited | Production method for purified dichloroacetic acid |
| EP4488282A4 (en) | 2022-03-23 | 2025-11-19 | Sumitomo Chemical Co | PROCESS FOR THE PRODUCTION OF NUCLEIC ACID OLIGOMERS |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| GB9621367D0 (en) * | 1996-10-14 | 1996-12-04 | Isis Innovation | Chiral peptide nucleic acids |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| WO2005019453A2 (en) * | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| US6962906B2 (en) * | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| US20060111312A1 (en) * | 2002-02-22 | 2006-05-25 | The John Hopkins University | Antigene locks and therapeutic uses thereof |
| US20040058886A1 (en) | 2002-08-08 | 2004-03-25 | Dharmacon, Inc. | Short interfering RNAs having a hairpin structure containing a non-nucleotide loop |
| NL1022811C2 (nl) * | 2003-02-28 | 2004-08-31 | Fountain Patents B V | Systeem en werkwijze voor opslag en transport van zeecontainers. |
| EP1608735A4 (en) * | 2003-04-03 | 2008-11-05 | Alnylam Pharmaceuticals | RNAI CONJUGATES |
| JPWO2005030960A1 (ja) * | 2003-09-30 | 2006-12-07 | アンジェスＭｇ株式会社 | ステイプル型オリゴヌクレオチドおよびそれからなる医薬 |
| WO2006088490A2 (en) * | 2004-06-30 | 2006-08-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
| WO2006074108A2 (en) * | 2004-12-30 | 2006-07-13 | Hauser Todd M | Compositions and methods for modulating gene expression using self-protected oligonucleotides |
| PL2129680T3 (pl) * | 2007-03-21 | 2015-10-30 | Brookhaven Science Ass Llc | Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji |
| CN101889087B (zh) * | 2007-11-29 | 2013-04-03 | 苏州瑞博生物技术有限公司 | 一种干扰靶基因表达的复合分子及其制备方法 |
| CA2930393C (en) * | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| WO2009076321A2 (en) * | 2007-12-07 | 2009-06-18 | Halo-Bio Rnai Therapeutics Inc. | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides |
| JP2010174915A (ja) | 2009-01-27 | 2010-08-12 | Toyota Motor Corp | 高圧ガスタンク |
| JP5449815B2 (ja) | 2009-03-26 | 2014-03-19 | 住友化学株式会社 | 偏光板の製造方法 |
| JP2010269823A (ja) | 2009-05-21 | 2010-12-02 | British American Tobacco Japan Kk | 喫煙品用容器 |
| JP2011152381A (ja) | 2010-01-25 | 2011-08-11 | Ucom:Kk | 箸置き |
-
2011
- 2011-07-28 ES ES13167541.5T patent/ES2533129T3/es active Active
- 2011-07-28 KR KR1020137004646A patent/KR101849801B1/ko active Active
- 2011-07-28 WO PCT/JP2011/067292 patent/WO2012017919A1/ja not_active Ceased
- 2011-07-28 ES ES13167536.5T patent/ES2528285T3/es active Active
- 2011-07-28 JP JP2011537085A patent/JP4965745B2/ja not_active Expired - Fee Related
- 2011-07-28 ES ES11748250.5T patent/ES2443346T3/es active Active
- 2011-07-28 KR KR1020187010010A patent/KR101894701B1/ko active Active
- 2011-07-28 CN CN201410217071.7A patent/CN104004018B/zh not_active Expired - Fee Related
- 2011-07-28 EP EP11748250.5A patent/EP2436767B1/en active Active
- 2011-07-28 CN CN201410217512.3A patent/CN104059911B/zh not_active Expired - Fee Related
- 2011-07-28 EP EP13184178.5A patent/EP2674494B1/en active Active
- 2011-07-28 EP EP13167541.5A patent/EP2639307B1/en active Active
- 2011-07-28 PT PT131841785T patent/PT2674494E/pt unknown
- 2011-07-28 CN CN201180037592.9A patent/CN103052711B/zh not_active Expired - Fee Related
- 2011-07-28 EP EP13167536.5A patent/EP2628801B1/en not_active Not-in-force
- 2011-07-28 KR KR1020187010011A patent/KR101894702B1/ko not_active Expired - Fee Related
- 2011-07-28 ES ES13184178.5T patent/ES2527660T3/es active Active
- 2011-07-28 DK DK13184178.5T patent/DK2674494T3/en active
- 2011-08-02 TW TW104132132A patent/TWI572716B/zh active
- 2011-08-02 TW TW100127384A patent/TWI515294B/zh not_active IP Right Cessation
-
2012
- 2012-02-10 JP JP2012026878A patent/JP5261677B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-12 JP JP2013048777A patent/JP5555346B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013138681A5 (enExample) | ||
| RU2016142510A (ru) | Соединения и способы для транс-мембранной доставки молекул | |
| JP5804642B2 (ja) | 遺伝子発現制御のための一本鎖核酸分子 | |
| JP5555346B2 (ja) | 含窒素脂環式骨格を有する一本鎖核酸分子 | |
| JP2011092201A5 (enExample) | ||
| WO2015093495A1 (ja) | ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子 | |
| JP6883349B2 (ja) | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 | |
| JP2020503049A5 (enExample) | ||
| JP2009504783A5 (enExample) | ||
| JP2016523087A5 (enExample) | ||
| EA034605B1 (ru) | Новые лиганды rig-i и способы их получения | |
| JP2021520387A (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| WO2019074110A1 (ja) | 一本鎖核酸分子およびその製造方法 | |
| JP2021502346A5 (enExample) | ||
| JP2013506720A5 (enExample) | ||
| JP6283859B2 (ja) | ペリオスチン遺伝子の発現抑制核酸分子、ペリオスチン遺伝子の発現抑制方法、およびその用途 | |
| WO2015099188A1 (ja) | 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途 | |
| EP3506910B1 (en) | Antisense oligonucleotides targeting prdm15 for treatment of cancer | |
| JPWO2015046451A1 (ja) | 眼科疾患を除くペリオスチン発現に起因する疾患用医薬、およびその用途 | |
| JP2009522281A5 (enExample) | ||
| WO2016098782A1 (ja) | ＴＧＦ－β１発現抑制のための一本鎖核酸分子 | |
| RU2020118025A (ru) | Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ их получения и применения |